David Pasquier

Dr. David Pasquier

orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2008 in International Journal of Radiation Oncology, Biology, Physics
Verified
Journal Article
Closed access
DPDavid Pasquier
David Pasquier
SBStefan Bijmolt
Stefan Bijmolt
TVTheo Veninga
Theo Veninga
NRNicolas Rezvoy
Nicolas Rezvoy
SFSalvador Villà Freixa
Salvador Villà Freixa
RMRené O. Mirimanoff
René O. Mirimanoff


1 June 2007 in International Journal of Radiation Oncology, Biology, Physics
Verified
Journal Article
Closed access
DPDavid Pasquier
David Pasquier
TLThomas Lacornerie
Thomas Lacornerie
MVMaximilien Vermandel
Maximilien Vermandel
JRJean Rousseau
Jean Rousseau
ELEric Lartigau
Eric Lartigau
NBNacim Betrouni
Nacim Betrouni

1 July 2004 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
DPDavid Pasquier
David Pasquier
THTobias Hoelscher
Tobias Hoelscher
JSJorg Schmutz
Jorg Schmutz
SDStanley Dische
Stanley Dische
DMDaniel Mathieu
Daniel Mathieu
ELEric Lartigau
Eric Lartigau

10 October 2022 in Radiotherapy and Oncology
Verified
Journal Article
Open access
TZThomas Zilli
Thomas Zilli
VAVérane Achard
Vérane Achard
APAlan Dal Pra
Alan Dal Pra
NSNina Schmidt-Hegemann
Nina Schmidt-Hegemann
BJBarbara Alicja Jereczek-Fossa
Barbara Alicja Jereczek-Fossa
CBClaus Belka
Claus Belka
Oligometastatic prostate cancer is a new and emerging treatment field with only few prospective randomized studies published so far. Despite the lack of strong level I evidence, metastasis-directed therapies (MDT) are widely used in clinical practice, mainly based on retrospective and small phase 2 studies and with a large difference across centers. Pending results of ongoing prospective randomized trials, there is a clear need for more consistent treatment indications and radiotherapy practices. A European Society for Radiotherapy and Oncology (ESTRO) Guidelines Committee consisting of radiation oncologists' experts in prostate cancer was asked to answer a dedicated questionnaire, including 41 questions on the main controversial issues with regard to oligometastatic prostate cancer. The panel achieved consensus on patient selection and routine use of prostate-specific membrane antigen positron emission tomography (PSMA PET) imaging as preferred staging and restaging imaging. MDT strategies are recommended in the de novo oligometastatic, oligorecurrent and oligoprogressive disease setting for nodal, bone and visceral metastases. Radiation therapy doses, volumes and techniques were discussed and commented. These recommendations have the purpose of providing standardization and consensus to optimize the radiotherapy treatment of oligometastatic prostate cancer until mature results of randomized trials are available.

3 August 2016 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
GDGrégory Delpon
Grégory Delpon
AEAlexandre Escande
Alexandre Escande
TRTimothée Ruef
Timothée Ruef
JDJulien Darréon
Julien Darréon
JFJimmy Fontaine
Jimmy Fontaine
DPDavid Pasquier
David Pasquier
Automated atlas-based segmentation algorithms present the potential to reduce the variability in volume delineation. Several vendors offer software that are mainly used for cranial, head and neck and prostate cases. The present study will compare the contours produced by a radiation oncologist to the contours computed by different automated atlas-based segmentation algorithms for prostate bed cases, including femoral heads, bladder and rectum. Contour comparison was evaluated by different metrics such as volume ratio, Dice coefficient and Hausdorff distance. Results depended on the volume of interest and showed some discrepancies between the different software. Automatic contours could be a good starting point for the delineation of organs since efficient editing tools are provided by different vendors. It should become an important help in the next few years for organ at risk delineation.